Stability, Efficacy, and Immunomodulatory Impact of Nanoemulsion-Encapsulated Lipoxin A4 in the context of pulpal inflammation
Abstract
Introduction: Lipoxin A4 (LXA4) is a specialized pro-resolving mediator with potential to modulate dental pulp inflammation. However, its therapeutic use is limited by instability and rapid degradation. This study aimed to develop and evaluate LXA4-loaded nanoemulsions (NELX) as a delivery system to promote inflammation resolution both in vitro and in vivo.Methods: NELX were formulated with LXA4 and characterized by dynamic light scattering, tunable resistive pulse sensing, scanning transmission electron microscopy, and liquid chromatography-tandem mass spectrometry. Encapsulation efficiency, stability, and drug payload were determined. In vitro, THP-1-derived macrophages (M0, M1, M2) were exposed to NELX, and metabolic activity, cytokine expression, and secretion were assessed. In vivo efficacy was investigated in a murine air pouch model and a rat molar pulpitis model. Histologic and immunohistochemical analyses (hematoxylin and eosin, CD68, CD163) were performed.Results: NELX achieved complete encapsulation (100%) of 20 μM LXA4 by day 3 and remained stable for 45 days at 4°C. In vitro, NELX preserved metabolic activity and promoted macrophage polarization toward an anti-inflammatory M2 phenotype, with increased IL10 and IL1RA expression and IL1RA secretion. In vivo, NELX reduced IL6 levels in the air pouch model and suppressed IL6 and IL1β secretion in the pulpitis model, with effects comparable to Ledermix™ Paste. Histology confirmed reduced inflammatory infiltration and enhanced recruitment of CD163+ macrophages.Conclusions: NELX provide a stable and effective delivery system for LXA4, promoting resolution of dental pulp inflammation through targeted immunomodulation. This strategy holds promise for novel biologically based anti-inflammatory therapies in endodontics.
Related
- Monoacetyldiacylglycerols as emerging immunomodulatory lipids in chronic inflammation: mechanisms, biology, and translational potential
- Probiotics in type 1 diabetes: immunomodulatory mechanisms and the unresolved question of clinical efficacy
- Non-B DNA at the Interface of Metabolism, Genome Stability, and Inflammation
- Safranal Enhances the Efficacy of Praziquantel Against Schistosoma mansoni Infection and Alleviates Liver Fibrosis, Inflammation and Oxidative Stress in Mice
- Dual-Component Nanoemulsion Containing Brugmansia suaveolens Leaf Extract and Copaiba Oil: Antimicrobial Activity and Preclinical Wound-Healing Potential
BibTeX
@article{guyon2026stability,
title = {{Stability, Efficacy, and Immunomodulatory Impact of Nanoemulsion-Encapsulated Lipoxin A4 in the context of pulpal inflammation}},
author = {Léna Guyon and Solène Tessier and Mikaël Croyal and Mathilde Gourdel and Hélène Terrisse and Joelle Veziers and Hélène Gautier and Pierre Weiss and Alexis Gaudin},
journal = {Journal of Endodontics},
year = {2026},
month = oct,
doi = {10.1016/j.joen.2026.08.015},
url = {https://hal.science/hal-05740610v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Stability, Efficacy, and Immunomodulatory Impact of Nanoemulsion-Encapsulated Lipoxin A4 in the context of pulpal inflammation
AU - Léna Guyon
AU - Solène Tessier
AU - Mikaël Croyal
AU - Mathilde Gourdel
AU - Hélène Terrisse
AU - Joelle Veziers
AU - Hélène Gautier
AU - Pierre Weiss
AU - Alexis Gaudin
PY - 2026
DA - 2026/10/08
JO - Journal of Endodontics
DO - 10.1016/j.joen.2026.08.015
UR - https://hal.science/hal-05740610v1
AB - Introduction: Lipoxin A4 (LXA4) is a specialized pro-resolving mediator with potential to modulate dental pulp inflammation. However, its therapeutic use is limited by instability and rapid degradation. This study aimed to develop and evaluate LXA4-loaded nanoemulsions (NELX) as a delivery system to promote inflammation resolution both in vitro and in vivo.Methods: NELX were formulated with LXA4 and characterized by dynamic light scattering, tunable resistive pulse sensing, scanning transmission electron microscopy, and liquid chromatography-tandem mass spectrometry. Encapsulation efficiency, stability, and drug payload were determined. In vitro, THP-1-derived macrophages (M0, M1, M2) were exposed to NELX, and metabolic activity, cytokine expression, and secretion were assessed. In vivo efficacy was investigated in a murine air pouch model and a rat molar pulpitis model. Histologic and immunohistochemical analyses (hematoxylin and eosin, CD68, CD163) were performed.Results: NELX achieved complete encapsulation (100%) of 20 μM LXA4 by day 3 and remained stable for 45 days at 4°C. In vitro, NELX preserved metabolic activity and promoted macrophage polarization toward an anti-inflammatory M2 phenotype, with increased IL10 and IL1RA expression and IL1RA secretion. In vivo, NELX reduced IL6 levels in the air pouch model and suppressed IL6 and IL1β secretion in the pulpitis model, with effects comparable to Ledermix™ Paste. Histology confirmed reduced inflammatory infiltration and enhanced recruitment of CD163+ macrophages.Conclusions: NELX provide a stable and effective delivery system for LXA4, promoting resolution of dental pulp inflammation through targeted immunomodulation. This strategy holds promise for novel biologically based anti-inflammatory therapies in endodontics.
SN - 0099-2399
ER -